Adductor spasticity in children with cerebral palsy and treatment with botulinum toxin type A: The parents' view of functional outcome

European Journal of Neurology

Volumn 6, Issue SUPPL. 4, 1999, Pages s47-s50

  Heinen, Florian ^a   Linder, Michaela ^a   Mall, Volker ^a   Kirschner, Janbernd ^a   Korinthenberg, Rudolf ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Adductor spasticity; Botulinum toxin type A; Cerebral palsy; Children; Disability; Functional benefit

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ADULT; BODY POSTURE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; FUNCTIONAL ASSESSMENT; GAIT; HUMAN; JOINT MOBILITY; MALE; MOTOR PERFORMANCE; PAIN; PRIORITY JOURNAL; QUESTIONNAIRE; SATISFACTION; SITTING; SPASTICITY; STANDING; TREATMENT OUTCOME; WALKING;

EID: 0033402890     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.1999.tb00034.x     Document Type: Conference Paper

References (15)

1. Bohannon RW, Smith MB (1987). Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 67:206-207.
2. Calderon-Gonzalez R, Calderon-Sepulveda R, Rincon-Reyes M, Garcia-Ramirez J, Mino-Arango E (1994). Botulinum toxin A in management of cerebral palsy. Pediatr Neurol 10:284-288.
3. Campbell SK (1996). Quantifying the effects of interventions for movement disorders resulting from cerebral palsy. J Child Neurol 11 (suppl 1):61-70.
4. Cosgrove AP, Corry IS, Graham HK (1994). Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 36:386-396.
5. Heinen F, Wissel J, Philipsen A, Mall V, Leititis JU, Schenkel A, et al. (1997). Interventional neuropediatrics: Treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 28:307-313.
6. Ketelaar M, Vermeer A, Helders PJM (1998). Functional motor abilities of children with cerebral palsy: a systematic literature review of assessment measures. Clin Rehab 12:369-380.
7. Koman LA, Mooney JF, Smith B, Goodman A, Mulvaney T (1993). Management of cerebral palsy with botulinum-A toxin: preliminary investigation. J Pediatr Orthopedics 13:489-495.
8. Krägeloh-Mann I, Hagberg G, Meisner C, Schelp B, Haas G, Eeg-Olofsson KE, et al. (1993). Bilateral spastic cerebral palsy - a comparative study between southwest Germany and western Sweden. I: clinical patterns and disabilities. Dev Med Child Neurol 35:1037-1047.
9. National Institutes of Health (1993). Research Plan for the National Center for Medical Rehabilitation Research. NIH Publications no. 93-3509. Washington, DC: US Department of Health and Human Services.
10. Palisano RJ, Haley SM, Brown DA (1992). Goal attainment scaling as a measure of change in infants with motor delays. Phys Ther 72:432-437.
11. Pascual-Pascual SI, Sanchez de Muniain P, Roche MC, Pascual-Castroviejo I (1997). La toxina botulínica como tratamiento de la parálisis cerebral infantil. Rev Neurol 25:1369-1675.
12. Russell DJ, Rosenbaum PL, Gowland C, Hardy S, Lane M, Plews N, et al. (1993). Manual for the Gross Motor Function Measure 2nd edition. Ontario, Canada: McMaster University.
13. Sanchez-Carpintero R, Narbona J (1997). Toxina botulínica en parálisis cerebral infantil: resultados en 27 sujetos a lo largo de un año. Rev Neurol 25:531-535.
14. Scheidt CE, Rayki O, Nickel T, Heinen F, Wissel J, Poewe W, et al. (1996). Spasmodic torticollis - a multicenter study on behavioural aspects Ii and methods. Behav Neurol 9:25-31.
15. Wright VF, Boschen K (1993). The Pediatric Evaluation of Disability Inventory (PEDI): validation of a new functional assessment outcome instrument. Can J Rehab 7:41-42.